bims-tuinly Biomed News
on Tumor-infiltrating lymphocytes therapy
Issue of 2026–11–22
34 papers selected by
Pierpaolo Ginefra, Ludwig Institute for Cancer Research



  1. Lab Invest. 2026 Nov 20. pii: S0023-6837(26)00113-3. [Epub ahead of print] 106183
       PURPOSE: Tumor-infiltrating lymphocytes (TILs) are associated with clinical outcomes in bladder cancer; however, conventional assessment methods are limited by subjective scoring and interobserver variability. We aimed to evaluate the prognostic significance of TILs at both the tumor center and invasive front using an artificial intelligence (AI)-based quantification approach across two independent bladder cancer cohorts.
    MATERIALS AND METHODS: We analyzed 84 patients with urothelial carcinoma who underwent TURB at a single institution. Pathologists selected tumor center and invasive front regions, and an AI pipeline combining tissue segmentation and lymphocyte detection measured the TIL ratio in each region. As an independent cohort, we analyzed The Cancer Genome Atlas bladder urothelial carcinoma (TCGA-BLCA) dataset, in which the two regions were identified by a whole-slide model with a pathologist-in-the-loop system. Each cohort was dichotomized at its respective median. Recurrence-free survival (RFS) and overall survival (OS) were analyzed using the Kaplan-Meier method, the log-rank test, and Cox regression.
    RESULTS: In the TURB cohort (75 patients with measurable central TILs, 44 recurrences), a high central TIL ratio was associated with longer RFS (log-rank p=0.019; hazard ratio [HR] 0.495, 95% confidence interval [CI] 0.271-0.902, p=0.022). This association remained significant in models adjusted for pathological T category and age. In the TCGA-BLCA cohort, our AI model detected tumor center and invasive front areas with a pathologist-in-the-loop system, and a high central (tumor center) TIL density was associated with longer RFS in 38 patients (p=0.022) and with longer OS in 77 patients (p=0.037). TIL density at the invasive front was not associated with outcomes in either cohort.
    CONCLUSIONS: AI-based quantification of TILs at the tumor center was associated with favorable survival outcomes across two independent bladder cancer cohorts, whereas measurements at the invasive front showed no significant prognostic association. These findings support the potential prognostic relevance of spatially resolved TIL assessment in bladder cancer and warrant further validation in larger, independent cohorts.
    Keywords:  The Cancer Genome Atlas; artificial intelligence; bladder cancer; deep learning; digital pathology; overall survival; recurrence-free survival; transurethral resection of bladder tumor; tumor-infiltrating lymphocytes
    DOI:  https://doi.org/10.1016/j.labinv.2026.106183
  2. J Clin Invest. 2026 Nov 16. pii: e204657. [Epub ahead of print]136(22):
      T cell engagers (TCEs) have achieved transformative success in B cell malignancies but show limited efficacy in solid tumors with severe toxicity. We propose that TCR signaling without IL-2 might limit the function of tumor-infiltrating lymphocytes (TILs). Here, we showed that insufficient IL-2 signaling is a key bottleneck for sustaining TCE-induced T cell function. Although exogenous IL-2 enhances TCE efficacy, its systemic administration causes more severe toxicity. We engineered a protease-activatable dual-variable domain (DVD) as a pro-antibody to reduce αCD3 off-tumor toxicity. Furthermore, we designed 3 additional mutations for IL-2 (3E) with markedly reduced receptor affinity, which remained inactive in the periphery. By coengineering the DVD and 3E into a single pro-drug molecule (DVD-3E), we achieved conditional IL-2 and TCR cosignaling strictly dependent on cis CD3 engagement within the tumor microenvironment (TME) upon protease cleavage. This logic-gated design restricted both TCE and cytokine activity to the TME, enabling potent antitumor responses without systemic toxicity. Mechanistically, DVD-3E enhanced not only the persistence and effector function of preexisting intratumoral T cells but also expanded TCF1+ TILs, mitigating exhaustion and enabling durable systemic immunity. These findings define a new design principle for logic-gated TCEs that achieve a favorable balance between efficacy and safety, offering a strategy to overcome current therapeutic resistance.
    Keywords:  Cytokines; Drug therapy; Immunology; Oncology; T cells
    DOI:  https://doi.org/10.1172/JCI204657
  3. Arch Pathol Lab Med. 2026 Oct 15. pii: e2025-0572-OA. [Epub ahead of print]
       Context.—: Several studies have reported the prognostic and therapeutic response value of tumor-infiltrating lymphocytes (TILs) and tertiary lymphoid structures (TLSs) in patients with melanoma. However, the prognostic correlation of these markers assessed by immunohistochemistry staining remains contradictory.
    Objective.—: To investigate the impact of TILs and TLSs on progression-free survival (PFS) and overall survival (OS) across melanoma subtypes.
    Design.—: Immunohistochemical staining for CD3, CD4, CD8, forkhead box protein 3 (FOXP3), CD20, and PD-L1 (programmed cell death-ligand 1) was combined with automated image analysis for density quantification. Cox regression and Kaplan-Meier analysis evaluated the effects of PD-L1 expression and TIL and TLS distribution on PFS and OS.
    Results.—: Clinicopathologic subtypes differed in multiple factors including TILs and immune cell counts. Kaplan-Meier analysis showed high intratumoral CD3+ (iCD3+), intratumoral CD8+ (iCD8+), and intratumoral CD20+ (iCD20+) cell counts and low peritumoral FOXP3+ (pFOXP3+) cell counts correlated with shorter OS; and high iCD8+ and iCD20+ cell counts and low intratumoral FOXP3+ (iFOXP3+), peritumoral CD4+ (pCD4+), and pFOXP3+ cell counts correlated with worse PFS. Multivariate Cox regression identified lymph node metastasis, iCD8+ and pFOXP3+ cells as independent OS prognostic factors; and mitotic count, lymph node metastasis, iCD8+ and iFOXP3+ cells as independent PFS prognostic factors.
    Conclusions.—: In this exploratory, hypothesis-generating study of Chinese patients with primary melanoma, TIL subgroups showed significant prognostic value, while PD-L1 expression did not. Owing to the modest sample size and single-center design, these findings require validation in larger, multicenter cohorts before clinical translation.
    DOI:  https://doi.org/10.5858/arpa.2025-0572-OA
  4. Cancer Immunol Immunother. 2026 Aug 18. pii: 276. [Epub ahead of print]75(11):
       BACKGROUND: The therapeutic potential of combining microwave ablation (MWA) with lymphocyte-activation gene 3 (LAG-3) blockade has been demonstrated in various cancers, while its specific efficacy and molecular mechanisms in hepatocellular carcinoma (HCC) remain unclear.
    METHODS: LAG-3 expression in clinical samples was investigated. LAG-3 expression in tumor-infiltrating lymphocytes (TILs) was further explored using HCC-bearing mice treated with MWA. Moreover, the survival rate, tumor growth, TIL recruitment, and CD8+ T cell function were monitored in mice treated with MWA and LAG-3 blockade. Further CXCL10 blockade or CD8 blockade strategies were employed to elucidate the underlying mechanisms of the anti-tumor immunity.
    RESULTS: LAG-3, CXCL10, CXCR3, and CD8 were highly expressed in human HCC tissues. MWA treatment elevated LAG-3 expression in subsets of TILs. In contrast to MWA or anti-LAG-3 therapy alone, the combination of MWA and anti-LAG-3 therapy exhibited a synergistic effect, resulting in prolonged survival, inhibited tumor growth, increased infiltration of TILs, elevated serum CXCL10 level, an enhanced population of CXCR3+CD8+ T cells, and increased CD8+ T cell cytotoxic activity in HCC-bearing mice. Furthermore, blockade of CXCL10 weakened the CD8+ T cell function in the combined therapy group. Additionally, CD8 blockade promoted tumor growth and impaired CD8+ T cell function under the combined treatment.
    CONCLUSION: MWA combined LAG-3 blockade emerged as a distinctive therapeutic approach for HCC, and the underlying mechanism is rooted in the CXCL10/CXCR3-mediated activation of CD8+ T cells.
    Keywords:  CD8+ T cells; CXCL10/CXCR3; Hepatocellular carcinoma (HCC); LAG-3; Microwave ablation (MWA)
    DOI:  https://doi.org/10.1007/s00262-026-04523-8
  5. J Dtsch Dermatol Ges. 2026 Nov 17.
      Cellular therapy is entering a new phase in solid tumors. For dermato-oncology, this shift is no longer theoretical: tumor-infiltrating lymphocyte (TIL) therapy is approved in the United States, and PRAME-directed T cell receptor (TCR) T cells provide the leading receptor-defined benchmark for melanoma. Chimeric antigen receptor (CAR) T cell therapy has entered early-phase clinical evaluation for melanoma and cutaneous lymphomas, with ongoing trials targeting GD2, IL13Rα2, NG2, DLL3, and CD30. Early clinical findings support the feasibility of this approach, demonstrate CAR T cell trafficking to tumor sites, and indicate an acceptable safety profile. The clinical challenge is therefore not conceptual but translational: selecting sufficiently tumor-restricted surface antigens, overcoming antigen heterogeneity, improving trafficking and persistence, and combining CAR T cells rationally with checkpoint blockade, targeted therapy, radiotherapy, or oncolytic strategies. This article summarizes the current clinical landscape and proposes a practical path toward biomarker-selected, combination-ready CAR T cell trials in advanced skin cancer.
    Keywords:  Adoptive cell therapy; CAR T cells; PRAME; TCR T cells; cutaneous lymphoma; dermato‐oncology; melanoma; tumor‐infiltrating lymphocytes
    DOI:  https://doi.org/10.1111/ddg.70578
  6. Cancer Immunol Res. 2026 Nov 17.
      Accessing tumor-reactive CD8⁺ T cells in patient blood is essential for non-invasive monitoring of systemic T cell responses and guiding personalized therapies. However, precise functional, molecular, and phenotypic characterization of these cells remains challenging. Here, we identify TIGIT as a functionally validated surrogate marker of tumor-reactive CD8⁺ T cells and define its associated transcriptional program to characterize circulating tumor-reactive CD8⁺ T cells in melanoma patients. We demonstrate that blood TIGIT⁺ CD8⁺ T cells mount robust cytotoxic responses against autologous tumor cells across multiple melanoma patient models, irrespective of PD-1 co-expression. At the clonotype level, TIGIT broadened detection of the circulating tumor-reactive repertoire beyond PD-1 while retaining high specificity. Moreover, circulating TIGIT⁺ CD8⁺ T cell population was closely associated with the intratumoral T cell repertoire and exhibited hallmarks of antigen experience, including effector memory differentiation, a hypomethylated DNA landscape, and increased clonal expansion. Longitudinal profiling of blood samples from melanoma patients undergoing immune checkpoint inhibition revealed an increased frequency of TIGIT⁺ CD8⁺ T cells in clinical responders. Finally, leveraging paired single-cell transcriptomic and TCR data from patient models with identified tumor-reactive clones, we show that the TIGIT-associated transcriptional program enables robust detection of circulating tumor-reactive CD8⁺ T cells. Collectively, our data establish TIGIT⁺ CD8⁺ T cells as a potent reservoir of tumor-reactive T cells in peripheral blood and provide a blood-based framework for accelerating TCR discovery and advancing adoptive cell therapy.
    DOI:  https://doi.org/10.1158/2326-6066.CIR-26-0327
  7. Res Sq. 2026 Nov 10. pii: rs.3.rs-10375256. [Epub ahead of print]
      Checkpoint-responsive exhausted CD8 + T cells sustain immunity during chronic infection and cancer, but the tissue-derived signals that preserve these cells remain poorly defined. Here, we identify extracellular ATP sensing through P2RX7 as a microenvironmental circuit that maintains progenitor exhausted (T PEX ) and tissue-resident exhausted (TR TEX ) CD8 + T cells. P2RX7 was enriched in T PEX and TR TEX cells and was required cell-intrinsically to preserve their abundance, diversity, and developmental competence during chronic viral infection. Loss of P2RX7 restricted early progenitor trajectories and induced mitochondrial dysfunction, lipid peroxidation, and terminal exhaustion-associated phenotypes. Mechanistically, P2RX7-dependent Ca 2+ influx activated NFAT/AP-1 signaling, which induced KLF3 to promote mitochondrial fitness, subset development, and persistence of T PEX and TR TEX cells. P2RX7 also supported CD8 + T cell expansion after PD-1 blockade, whereas pharmacologic P2RX7 activation enhanced antitumor immunity in preclinical models. These findings define an extracellular ATP-P2RX7-KLF3 program that couples tissue damage sensing to metabolic adaptation and persistence of checkpoint-responsive exhausted CD8 + T cells.
    DOI:  https://doi.org/10.21203/rs.3.rs-10375256/v1
  8. Cancer Control. 2026 Jan-Dec;33:33 10732748261510211
      IntroductionAdvanced gastric cancer has a poor prognosis, and reliable biomarkers for identifying patients who may benefit from immune checkpoint inhibitors (ICIs) combined with chemotherapy remain limited. Dynamic alterations in the tumor microenvironment (TME) may provide clinically useful information regarding treatment response. This study aims to investigate longitudinal TME changes in patients with advanced gastric cancer receiving ICIs plus chemotherapy and to explore their associations with treatment response.MethodsThis is a prospective, single-center biomarker study in patients with advanced gastric cancer receiving ICIs plus chemotherapy. Matched tumor tissue samples from primary and/or metastatic lesions, together with peripheral blood samples, will be collected before treatment and after four cycles of combination therapy. Patients achieving complete response (CR) or partial response (PR) will be classified as the high-response group (HRG), whereas patients with progressive disease (PD) will be classified as the non-response group (NRG). Pre- and post-treatment TME alterations will be analyzed within each patient, and differences between the HRG and NRG will be compared, including tumor-infiltrating lymphocytes (TILs), H3K4me3, cytokines, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and tumor markers. Associations with programmed death-ligand 1 (PD-L1), mismatch repair (MMR), and Epstein-Barr virus-encoded RNA (EBER) status will also be explored.ConclusionsThis study may identify dynamic TME-related biomarkers associated with response to ICIs combined with chemotherapy, and may provide evidence for future response-stratification strategies in advanced gastric cancer.
    Keywords:  Advanced GC; H3K4me3; ICIs; TILs; TME; cytokines
    DOI:  https://doi.org/10.1177/10732748261510211
  9. Cancer Immunol Immunother. 2026 Aug 22. pii: 284. [Epub ahead of print]75(12):
      The development of immune checkpoint inhibitors has improved the treatment outcomes for patients with many types of cancer. However, the clinical benefits remain limited in many patients, highlighting the need for novel therapeutic strategies to enhance antitumor immunity. Hepatocyte nuclear factor 1A (HNF1A) is a transcription factor that regulates the expression of several liver-specific genes, and its expression is increased in certain cancers, such as colon and non-small cell lung cancer (NSCLC), compared with normal tissue. However, the effects of HNF1A on antitumor immunity remain unknown. Here, we show that colon cancer and NSCLC expressing HNF1A activate antitumor immunity. HNF1A-overexpressing cancer cells activated T-cell-mediated anticancer cytotoxicity when co-cultured with peripheral blood mononuclear cell-derived T cells. In a syngeneic mouse model, MC38 colon adenocarcinoma growth was suppressed after subcutaneous injection of HNF1A-overexpressing cancer cells. Flow cytometry analysis of tumor-infiltrating T cells showed that CD8+ T cells increased and were functionally activated in tumors overexpressing HNF1A. Treatment with an anti-PD-1 monoclonal antibody reduced tumor growth in HNF1A-overexpressing tumors. These results suggest that HNF1A plays a role in antitumor immunity and may influence the response to immune checkpoint blockade.
    Keywords:  Antitumor immunity; Colon cancer; Hepatocyte nuclear factor 1A (HNF1A); Non-small cell lung cancer; Programmed cell death 1 (PD-1); Tumor-infiltrating lymphocytes
    DOI:  https://doi.org/10.1007/s00262-026-04533-6
  10. bioRxiv. 2026 Nov 10. pii: 2026.11.09.765236. [Epub ahead of print]
      The presence of polyfunctional T cells capable of concurrently producing multiple cytokines correlates with favorable clinical outcomes in patients with cancer. We previously reported that overexpression of constitutively active Stat5a (CASTAT5) confers polyfunctionality on tumor-specific CD4⁺ T cells, enabling durable antitumor immunity following adoptive cell therapy. However, the mechanisms underlying the enhanced antitumor effects of CASTAT5-modified T cells remain unclear. Here, we identify interleukin-13 (IL13) as a critical effector cytokine contributing to the multifaceted antitumor activity of CASTAT5-conditioned polyfunctional CD4⁺ T cells (C5-CD4). C5-CD4 T cells exhibit a prominent T helper 2 (Th2) cytokine profile, accompanied by extensive epigenomic remodeling at the Th2 cytokine loci, as revealed by Hi-C and histone-modification CUT&Tag assays. Neutralization of IL13 diminished the antitumor efficacy of C5-CD4 T cells. Furthermore, targeted Il13 disruption substantially impaired tumor control and was associated with reduced donor T cell expansion and persistence, diminished systemic cytokine and chemokine responses, and attenuated activation of endogenous tumor-reactive CD8⁺ T cells. Nonetheless, IL13 overexpression alone in donor CD4⁺ T cells failed to fully recapitulate the therapeutic activity of C5-CD4 T cells, indicating that IL13 is a critical contributor but is insufficient to account for the full antitumor activity conferred by CASTAT5. Single-cell RNA sequencing associated donor-derived IL13 with increased representation of tumor-infiltrating myeloid cells and IL13-signaling in monocytes and macrophages exhibiting tissue-repair-associated transcriptional programs. Moreover, Il13 disruption diminished the therapeutic efficacy of CASTAT5-expressing CD19-targeted CAR-T cells in a mouse B-cell lymphoma model. Reanalysis of a human CD19CAR-T infusion-product dataset further revealed an association between IL13 expression and type 2 cytokine signatures linked to prolonged clinical response, suggesting a potential contribution of IL13 to the efficacy of human CD19CAR-T therapy. Together, these findings uncover an unexpected antitumor role for IL13 and establish it as a critical node linking polyfunctional donor T cells with endogenous immune cells to promote sustained tumor immunity.
    DOI:  https://doi.org/10.64898/2026.11.09.765236
  11. Cancer Immunol Res. 2026 Nov 19.
      CAR-T cells have yet to show widespread efficacy in solid tumors due in part to poor persistence and dysfunction in the tumor microenvironment. Further, heterogenous expression of target antigens can lead to escape of antigen-null tumors that resist CAR-T killing. Strategies to cooperatively boost both CAR-T and endogenous antitumor immunity may be critical for achieving durable efficacy in cancer patients. NKTR-255 is a polymer-conjugated IL-15 with extended half-life that can boost endogenous T and NK cells, as well as CD19 CAR-T cells in B cell malignancies. However, whether NKTR-255 is sufficient to overcome CAR-T dysfunction in the suppressive solid tumor microenvironment, and how NKTR-255 and CAR-Ts together re-shape endogenous antitumor immunity, is not known. Using mouse models of ROR1+ lung adenocarcinoma, we show that NKTR-255 significantly boosted accumulation and function of tumor-infiltrating CAR-T cells targeting ROR1. Compared with NKTR-255 or CAR-T treatment alone, combination of NKTR-255 and CAR-T therapy increased endogenous tumor-specific T cells that preserved a PD-1+Tcf1+ stem-like phenotype. Consequently, NKTR-255 and CAR-T combination therapy completely eliminated ROR1+ tumor cells and significantly improved survival, with enhanced tumor control dependent on both CAR-Ts and endogenous T cells, though all mice ultimately succumbed to progression of ROR1- tumor. Compared to IL-15-armored CAR-T cells, systemic NKTR-255 induced greater accumulation and reduced terminal differentiation of endogenous tumor-specific T cells, resulting in superior tumor control. Thus, combining NKTR-255 with CAR-T therapy is a promising strategy to enhance both CAR-T and endogenous antitumor immunity to promote coordinated control of aggressive tumors.
    DOI:  https://doi.org/10.1158/2326-6066.CIR-25-1569
  12. Proc Natl Acad Sci U S A. 2026 Nov 24. 123(47): e2623940123
      The efficacy of adoptive cell therapies depends on the presence of T cells with durable self-renewal, proliferative capacity, and differentiation potential, yet heterogeneity within starting cell populations remains a major barrier to consistent clinical outcomes. Here, we identify CD49f as a marker of a unique subset of human memory T cells with stem-like characteristics. CD49fHi memory CD8+ and CD4+ T cells exhibited transcriptional and phenotypic features associated with T cell stemness, including elevated LEF1, TCF1, CCR7, CD27, and CD28, while CD49fLo cells exhibited effector-like transcriptional programs. Clinical evaluation of solid-organ transplant recipients treated with virus-specific T cells for cytomegalovirus complications demonstrated that autologous T cell therapies manufactured from CD49fHi-enriched T cells were associated with superior immune reconstitution and greater in vivo expansion of CMV-specific T cells. Functional assays further revealed that CD49fHi memory T cells possessed enhanced proliferative capacity and transcriptional plasticity following activation. Consistent with these findings, CD19 CAR T cells engineered from CD49fHi memory T cells demonstrated improved persistence and conferred superior survival in a preclinical lymphoma model. Together, these findings establish CD49f as a marker of a stem-like memory T cell subset with enhanced therapeutic potential and identify CD49fHi enrichment as a practical strategy to improve the consistency, durability, and clinical efficacy of both virus-specific and CAR T cell therapies.
    Keywords:  CD49f; T cells; immunotherapy; stem-Like; stem-like
    DOI:  https://doi.org/10.1073/pnas.2623940123
  13. Commun Med (Lond). 2026 Jul 28. pii: 595. [Epub ahead of print]6(1):
       BACKGROUND: The abscopal effect, in which radiotherapy of one tumor is associated with regression of distant non-irradiated tumors, remains uncommon even when combined with immune checkpoint blockade. Although systemic T cell priming is required, the mechanisms that determine whether effector T cells persist within distant tumors remain unclear. We investigated whether SFRP2-expressing stromal cells limit CD8+ T cell stress resilience in abscopal tumors.
    METHODS: We used bilateral mouse tumor models treated with fractionated radiotherapy plus anti-PD-1 antibody, combined with immune profiling of irradiated tumors, tumor-draining lymph nodes, and distant tumors. Human lung cancer specimens, public transcriptomic datasets, fibroblast-specific Sfrp2 deletion, single-cell RNA sequencing, immunostaining, flow cytometry, and fibroblast-T cell co-culture assays were used to examine the relationship between SFRP2, CD8+ T cell apoptosis, and stress-response signaling. Statistical analyses included two-sided tests and multiple-comparison correction where appropriate.
    RESULTS: Here we show that radioimmunotherapy activates local tumor immunity and tumor-draining lymph node priming, but resistant distant tumors fail to maintain CD8+ T cell accumulation. SFRP2 is enriched in fibroblast-like stromal compartments and is inversely associated with CD8+ T cell infiltration. Fibroblast-specific Sfrp2 deletion reduces CD8+ T cell apoptosis and restores an HSPA1A/HSP70-associated stress-resilience program. Mechanistically, SFRP2 suppresses a WNT-HSF1-HSPA1A signaling program, whereas Hspa1a overexpression reduces SFRP2-associated caspase-3 activation in T cells.
    CONCLUSIONS: These findings identify stromal suppression of CD8+ T cell stress resilience as a mechanism of abscopal resistance and support SFRP2-WNT-HSF1 pathway targeting as a potential strategy to improve radioimmunotherapy.
    DOI:  https://doi.org/10.1038/s43856-026-01829-7
  14. Front Immunol. 2026 ;17 1968249
      In triple-negative breast cancer (TNBC), tumor immune microenvironment (TIME) is highly heterogeneous and constitutes a key determinant of response to immunotherapy. Nevertheless, current clinical assessment of biomarkers, notably programmed death-ligand 1 (PD-L1) expression and tumor-infiltrating lymphocytes (TILs), relies primarily on static and localized tissue sampling, constrained by spatial heterogeneity, sampling bias, and lack of longitudinal assessment, which limits its capacity to fully represent the evolving TIME and support adaptive treatment decision-making. Artificial intelligence (AI)-driven radiomics has emerged as a non-invasive framework enabling the conversion of routine imaging into high-throughput biomarkers, capturing TIME imaging phenotypes. When integrated with genomic data, this strategy extends into radiogenomics, allowing the association of radiomics features with underlying molecular features to better characterize the TNBC landscape. However, given the inter/intra-diversity of TNBC-TIME, integrating complementary multi-omics layers becomes necessary to fully reflect TIME landscape and represent the interplay between TIME components. Several findings from studies on solid tumors, including TNBC, suggest that AI-derived radiomics signatures are associated with immune and molecular patterns and may predict PD-L1 expression, TILs, TIME phenotypes and response to immune checkpoint blockade. Beyond static and isolated biomarker development, 'Immuno-Radio-Multi-Omics' could enable dynamic non-invasive whole-tumor immune profiling, enhanced patient stratification, and support the future development of longitudinal and adaptive therapeutic strategies. Meanwhile, its clinical translation is currently limited by the lack of large and prospective datasets, standardization, validation and interpretability. Through this mini-review, we aim to critically discuss current evidence, limitations and next frontiers of 'Immuno-Radio-Multi-Omics' in TNBC, emphasizing its potential to advance dynamic and personalized immunotherapy strategies in TNBC.
    Keywords:  Immuno-Radio-Multi-Omics; artificial intelligence; immunotherapy response; multi-omics; radiomics; triple-negative breast cancer
    DOI:  https://doi.org/10.3389/fimmu.2026.1968249
  15. J Exp Clin Cancer Res. 2026 Aug 28. pii: 241. [Epub ahead of print]45(1):
       BACKGROUND: Resistance to immune checkpoint inhibition (ICI) using antibodies against the PD-1/PD-L1 axis remains a significant clinical challenge. Here, we report that combination of anti-PD-1 with a bifunctional fusion molecule, anti-TCRβ-IL-2, comprised of a monovalent Fab that binds and activates the T-cell receptor (TCR) through distinct variable beta (Vβ) chain residues and an IL-2 molecule, mediates robust anti-tumor control in the context of ICI resistance.
    METHODS: Syngeneic murine models with varying levels of ICI-resistance were used to assess sensitization to ICI in combination with the anti-TCRβ-IL-2 therapy. Mechanisms of the combination therapy's benefit were investigated by profiling tumor-infiltrating lymphocytes via flow cytometric, single cell transcriptomic, and histological analyses. Immune response efficacy and diversification was identified by the generation of multifunctional, tumor-associated antigen-specific and neoantigen-specific T-cell responses post-therapy.
    RESULTS: Unlike anti-PD-1 therapy alone that resulted in expansion of terminally exhausted CD8+ T cells and lack of anti-tumor effect, administration of anti-TCRβ-IL-2 followed by anti-PD-1 greatly enhanced anti-tumor efficacy leading to tumor cures and long-term protection in several murine models resistant to ICI. Analysis of tumor-infiltrating lymphocytes showed increased proliferation and markers of cytotoxicity in CD8+ and CD4+ T cells, reduced CD8+ T-cell exhaustion, and decreased proportion of regulatory CD4+ T cells in tumors of mice receiving TCRβ-IL-2 followed by anti-PD-1. Diversification of the immune response with increased number of multifunctional, neoantigen-specific T cells was observed in mice receiving anti-TCRβ-IL-2 followed by anti-PD-1, compared to each of the monotherapies.
    CONCLUSIONS: A novel T-cell activation mechanism sensitizes refractory tumors to ICI via T-cell function revival and epitope spreading. From these results, a clinical trial is planned to evaluate the combination of an anti-TCRβ-IL-2 agent (invikafusp alfa) and anti-PD-1 in ICI-refractory non-small cell lung and castration-resistant metastatic prostate cancers.
    Keywords:  ICI resistance; Immunotherapy combination; TCR targeting
    DOI:  https://doi.org/10.1186/s13046-026-03815-2
  16. Cell Stem Cell. 2026 Nov 20. pii: S1934-5909(26)00397-8. [Epub ahead of print]
      Strategies to provide less-differentiated naive T cell clones in patients with cancer and immunodeficiencies are expected to improve the efficacy of immunotherapies. Adoptive transfer of T cell progenitors with thymus-seeding progenitors (TSPs) differentiated from human induced pluripotent stem cells (iPS cells) represents a potential approach to provide histocompatible naive T cell clones. In contrast to mature T cells, the generation of TSPs from human iPS cells remained a challenge. Here, we identified a chemically defined condition to generate VE-cadherin+CD34hiCD7med TSP-like cells (iTSPs) from human iPS cell-derived hemogenic endothelial cells (HECs). The differentiated cells engrafted into the thymus of immunodeficient mice and yielded CCR7+CD45RA+CD62L+TCF7+ naive T cells expressing a diverse T cell receptor (TCR) repertoire. iTSPs expressing a CD19-targeting chimeric antigen receptor (CAR) differentiated into CAR T cells in recipients and mediated antitumor activity against CD19+ leukemia. Together, these findings establish a platform for generating human iTSPs and provide developmental insight into naive-like T cell generation in vivo.
    Keywords:  T cell progenitors; T cells; adoptive cell therapy; chimeric antigen receptors; gene engineering; hematopoietic progenitors; immunotherapy; in vitro differentiation; induced pluripotent stem cells; naive T cells
    DOI:  https://doi.org/10.1016/j.stem.2026.10.016
  17. Inflamm Res. 2026 Nov 20. pii: 262. [Epub ahead of print]75(1):
      The ability to modulate the tumor microenvironment emerges as a compelling strategy to stimulate antitumor immunity in solid tumors. In this context, innate immune cells, especially macrophages, are interesting targets for immunotherapies. Approaches based on CRISPR to delete specific suppressive molecules in these cells might lead to antitumor immunity. The target molecules to be depleted will depend on the type of tumor, since the tumor microenvironment and its immune-suppressive regulators can vary. This correspondence aims to discuss published animal models and stimulate research in this critical subject for the improvement of immunotherapies targeting macrophages. New therapeutic strategies, including epigenetic modifications to stabilize the proinflammatory phenotypes of these cells, are underscored.
    Keywords:  Innate immunity; Macrophages; Tumor immunotherapy; Tumor microenvironment
    DOI:  https://doi.org/10.1007/s00011-026-02410-7
  18. J Immunother Cancer. 2026 Nov 16. pii: e016004. [Epub ahead of print]14(11):
      
    Keywords:  Immunotherapy; Skin Cancer; Solid tumor; Tumor infiltrating lymphocyte - TIL
    DOI:  https://doi.org/10.1136/jitc-2026-016004
  19. Cell Commun Signal. 2026 Aug 22. pii: 616. [Epub ahead of print]24(1):
       BACKGROUND: CD8+ T lymphocytes are critical for rejecting cancer cells but often lose functionality in the immunosuppressive tumor microenvironment. Understanding this process could improve cancer immunotherapy. The enzyme GGPS1, which produces geranylgeranyl pyrophosphate (GGPP), has an unclear impact on CD8+ T cell cytotoxic function and tumor immune escape in clear cell renal cell carcinoma (ccRCC).
    METHODS: To investigate how GGPS1 deficiency in T cells affects tumor progression, we established Renca tumor models in mice with T-cell-specific deletion of GGPS1. A combination of approaches-including real-time PCR, western blotting, flow cytometry, in vitro cytotoxicity assays, Seahorse metabolic analysis, and measurements of glucose uptake and lactic acid secretion-was employed to dissect the role of GGPS1 in CD8⁺ T cell cytotoxicity and glycolysis. In parallel, adoptive transfer studies were conducted to evaluate the antitumor potential of CD8⁺ T cells engineered to overexpress GGPS1.
    RESULTS: CD8⁺ T cells isolated from ccRCC patients who failed to respond to PD-1 blockade exhibited markedly lower GGPS1 expression. In mice, T-cell-specific deletion of GGPS1 accelerated tumor growth, accompanied by diminished infiltration of cytotoxic CD8⁺ T cells and elevated expression of exhaustion markers-including PD-1, TIM-3, LAG-3, and TOX-on tumor-infiltrating CD8⁺ T cells. Silencing GGPS1 impaired cytokine production and antitumor activity, whereas restoring GGPS1 expression reinforced both functions. Notably, exogenous GGPP fully rescued the defects in cytotoxicity and glycolysis induced by GGPS1 knockdown. Mechanistically, GGPS1 promoted MEK/ERK signaling, and the MEK inhibitor trametinib abolished GGPP-driven enhancement of CD8⁺ T cell cytotoxicity and glycolysis. Finally, elevating GGPS1 levels in CD8⁺ T cells boosted the efficacy of both adoptive immunotherapy and immune checkpoint blockade in ccRCC models.
    CONCLUSIONS: These findings highlight the essential function of GGPS1 in regulating glycolysis and cytotoxicity in CD8+ T cells, offering potential therapeutic strategies for clinical tumor immunotherapy in ccRCC.
    Keywords:  GGPS1; Glycolysis; Immunotherapy; T cell
    DOI:  https://doi.org/10.1186/s12964-026-03167-6
  20. J Immunother Cancer. 2026 Nov 19. pii: e015140. [Epub ahead of print]14(11):
      
    Keywords:  Cytokine; Immune Checkpoint Inhibitor; T cell; Tumor Microenvironment
    DOI:  https://doi.org/10.1136/jitc-2026-015140
  21. J Immunol Methods. 2026 Nov 20. pii: S0022-1759(26)00111-0. [Epub ahead of print] 114135
      Mucosal-associated invariant T (MAIT) cells use semi-invariant T cell receptors that recognize microbial vitamin B₂ metabolites presented by MR1 molecules to bridge innate and adaptive immunity. There is growing interest in harnessing this distinct role in host defense to develop new immunotherapies, but scalable and efficient methods for ex vivo MAIT cell expansion are still needed. Herein, we devised a workflow for ex vivo expansion of human MAIT cells in which CD8+ T cells are enriched from peripheral blood mononuclear cells and stimulated for 14 days with streptavidin-coated polystyrene microspheres functionalized with biotinylated agonist anti-CD28 antibody and biotinylated human MR1 monomers loaded with 5-OP-RU, in interleukin-2-supplemented media. This approach significantly expanded human MAIT cells displaying potent effector function, as defined in intracellular cytokine staining assays that measured levels of IFN-γ, TNF, and IL-17 produced in response to TCR-dependent stimulation. This effector function was also preserved when expanded MAIT cells were thawed after cryopreservation, indicating cryopreservation did not impair functional integrity. Xeno-free, serum-replacement media partially supported MAIT cell expansion and purity compared with FBS-supplemented RPMI, suggesting a path toward cGMP-compatible manufacturing. Together, these findings establish a reliable workflow for robust ex vivo MAIT cell expansion and creates a flexible platform for understanding MAIT cell-mediated immunity and developing MAIT cell-based immunotherapeutics.
    Keywords:  5-OP-RU; Cryopreservation; Ex vivo expansion; MAIT cell function; MAIT cells; MR1; Microspheres
    DOI:  https://doi.org/10.1016/j.jim.2026.114135
  22. J Vet Intern Med. 2026 Nov 02. pii: aalag299. [Epub ahead of print]40(6):
       BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is the most common histologic subtype of lymphoma in dogs. Although using cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy is the standard treatment, outcomes remain suboptimal, emphasizing the need for novel therapeutic strategies.
    HYPOTHESIS/OBJECTIVES: Evaluate the feasibility and potential therapeutic benefit of adoptive immunotherapy using ex vivo-expanded cytokine-activated anti-tumor lymphocytes (CATLs) in dogs with DLBCL treated using CHOP chemotherapy and an autologous tumor vaccine.
    ANIMALS: Seven client-owned dogs with naturally occurring DLBCL.
    METHODS: Dogs received CHOP-based chemotherapy and the APAVAC® autologous vaccine. Peripheral blood mononuclear cells (PBMCs) were expanded ex vivo for 14 days using interleukin-2 and anti-CD3/CD28 stimulation. The CATLs were characterized by flow cytometry and reinfused.
    RESULTS: Peripheral blood mononuclear cells were successfully expanded. After 14 days, the median cell yield was 728 × 106 cells (range, 162.4 × 106-1 500 × 106), corresponding to a median 8.6-fold expansion. Median fold increases of positive cells were 7.23 (interquartile range [IQR], 6.46-9.64) for CD3+, 8.56 (IQR, 7.11-14.56) for CD4+, 8.41 (IQR, 6.24-9.29) for CD5+, 10.35 (IQR, 7.63-14.67) for CD8+, and 16.16 (IQR, 12.22-30.40) for CD4+CD8+ cells. Reinfused CATLs ranged from 162.4 × 106 to 1 500 × 106 cells.
    CONCLUSIONS AND CLINICAL IMPORTANCE: Ex vivo expansion and reinfusion of autologous CATLs in dogs with DLBCL receiving CHOP chemotherapy and APAVAC® vaccination are feasible and induce robust T-cell expansion, suggesting this combined chemo-immunotherapeutic approach may enhance anti-tumor immunity and warrants further investigation in larger clinical studies.
    Keywords:  CATLs; DLBCL; adoptive immunotherapy; autologous vaccine
    DOI:  https://doi.org/10.1093/jvimsj/aalag299
  23. Adv Radiat Oncol. 2026 Nov;11(11): 102138
       Purpose: Radiation therapy (RT) delivered at conventional dose rates (CONV RT) can both stimulate antitumor immune responses and inhibit them by depleting circulating lymphocytes. Given the observed normal tissue sparing associated with ultrahigh-dose-rate (FLASH) RT, we hypothesized that it may protect lymphocytes while increasing the immunogenicity of human papillomavirus (HPV)-positive tumors.
    Methods and Materials: We irradiated HPV-positive cancer cell lines, TC-1 and mEER, in vitro with either FLASH RT or CONV RT and assessed immunogenic messenger RNA and protein expression; we also irradiated tumors in syngeneic C57BL/6 mice with 27 Gy in 3 fractions with FLASH RT or CONV RT and assessed changes in lymphocyte populations.
    Results: Both cell lines showed upregulation of Calr, Hmgb1, and cGAS-STING family members after FLASH RT but not after CONV RT in vitro. In tumor-bearing mice treated with FLASH-RT, tumor-draining lymph nodes had greater numbers of CD8+ T cells (1.7 × 104 vs 0.8 × 104 CONV RT; P < .001) and CD4+ T cells (2.3 × 104 vs 1.2 × 104 CONV RT; P < .001). FLASH RT was also associated with an increased number of antigen-experienced CD44+CD62LloCD8+ and CD4+ lymphocytes. In irradiated tumors, FLASH RT was associated with increased CD8+ tumor-infiltrating lymphocytes, increased program cell death protein 1 (PD-1) expression on these lymphocytes, and increased programmed death-ligand 1 expression on macrophages. Compared with CONV RT, FLASH RT spared antigen-experienced effector-like T cells in tumors and in tumor-draining lymph nodes, but showed higher intratumoral CD8+ T cell counts with increased checkpoint inhibitor PD-1 expression.
    Conclusions: These results indicate that FLASH RT preserves lymphocyte numbers while maintaining radiation-induced immunogenic signaling, suggesting that FLASH RT supports antitumor responses in HPV-positive cancer models. This response may be further amplified by combining FLASH RT with immune checkpoint blockade.
    DOI:  https://doi.org/10.1016/j.adro.2026.102138
  24. Cell Commun Signal. 2026 Aug 27. pii: 626. [Epub ahead of print]24(1):
       BACKGROUND: Hepatocellular carcinoma (HCC) is a major cause of cancer mortality, necessitating therapies that bridge local tumor control with systemic anti-tumor immunity. While multimodal thermal therapy (MTT) can induce immunogenic responses, the precise molecular programs governing antigen-driven cytotoxic CD8⁺ T-cell immunity following ablation remain undefined. This study aims to delineate the transcriptional mechanisms driven by MTT that govern CD8⁺ T-cell mediated anti-tumor immunity.
    METHODS: Integrated single-cell transcriptomic profiling and proteomic analyses were performed on clinical samples obtained from HCC patients treated with MTT. Functional assays, including cytokine production, cytotoxicity analyses, and molecular interaction studies, were used to characterize CD8⁺ T-cell effector programs. Genetic manipulation and conditional knockout models were employed to interrogate the mechanistic role of key regulatory factors in vivo using murine HCC models. Statistical analyses were conducted using appropriate parametric or nonparametric tests as indicated, with significance determined based on standard criteria.
    RESULTS: Single-cell RNA sequencing revealed that MTT drives a distinct differentiation trajectory of CD8+ T cells toward a highly cytotoxic state, which was strongly associated with elevated expression of the nuclear receptor RORA. CD8 + T cells isolated from MTT-treated tumor-bearing mice exhibited a robust anti-tumor effector program characterized by increased production of IFN-γ, Perforin, Granzyme-B, and the chemokines CXCL9 and CXCL10, resulting in enhanced tumor cell killing. Mechanistically, the RNA-binding protein PTBP1 was identified as a critical co-activator of RORA. MTT treatment upregulated PTBP1, which directly interacted with RORA, facilitated its nuclear import, and promoted its recruitment to the promoters of cytotoxic effector genes. In murine HCC models, elevated RORA expression in CD8+ T cells was associated with enhanced anti-tumor responses following MTT. Notably, conditional deletion of Rora in CD8+ T cells completely abrogated the therapeutic efficacy of MTT.
    CONCLUSIONS: This study identifies the PTBP1-RORA axis as a central transcriptional regulator of CD8+ T-cell mediated anti-tumor immunity induced by multimodal thermal therapy. Our findings provide mechanistic insight into how MTT initiates systemic anti-tumor immune remodeling and reshapes cytotoxic T-cell function highlight PTBP1-RORA signaling as a promising biomarker and therapeutic target for enhancing cancer immunotherapy in HCC.
    Keywords:  Anti-tumor immunity; CD8⁺ T cells; Hepatocellular carcinoma; Multimodal thermal therapy; RORA–PTBP1 axis; Transcriptional regulation
    DOI:  https://doi.org/10.1186/s12964-026-03130-5
  25. J Extracell Vesicles. 2026 Nov;pii: e70384. [Epub ahead of print]15(11):
      Engineered biomimetic nanovesicle systems represent an emerging strategy for targeted immune modulation in cancer. In this study, we developed anti-CD8a-functionalized red blood cell membrane-derived nanovesicles (NVE) to selectively deliver the NFAT5 inhibitor KRN2 to CD8+ T cells. Transcriptomic and single-cell RNA sequencing analyses identified NFAT5 as a transcriptional regulator associated with PD-1 expression in highly exhausted CD8+ T cell subsets in cardia cancer. CD8a-NVE@KRN2 showed favourable physicochemical properties, efficient KRN2 loading, and preferential CD8+ T cell targeting. Functionally, targeted NFAT5 inhibition restored CD8+ T cell activity, promoted granzyme A-gasdermin B-mediated tumour cell pyroptosis, and indirectly shifted tumour-associated macrophages toward a more inflammatory, glycolysis-associated phenotype. In subcutaneous and orthotopic models, CD8a-NVE@KRN2 enhanced the antitumour effect of anti-PD-1 therapy. These findings support functionalized red blood cell membrane nanovesicles as a biomimetic platform for coordinated immune reprogramming in cancer.
    Keywords:  CD8+ T Cells; NFAT5; cardia cancer; pyroptosis; red blood cell membrane nanovesicles
    DOI:  https://doi.org/10.1002/jev2.70384
  26. Acta Biomater. 2026 Nov 16. pii: S1742-7061(26)00784-1. [Epub ahead of print]
      Immune checkpoint blockade has substantially improved outcomes in non-small cell lung cancer (NSCLC), although durable responses remain limited in a large fraction of patients. Increasing evidence links this resistance to epithelial-mesenchymal transition (EMT), a cellular program that not only enhances invasiveness but also restricts T-cell access within the tumor microenvironment. By integrating transcriptomic profiles from immunotherapy-resistant lung cancer organoids with The Cancer Genome Atlas Lung Adenocarcinoma cohort (TCGA-LUAD) and independent immunotherapy datasets, we identified twist family bHLH transcription factor 1 (TWIST1) as a central epithelial-mesenchymal transition (EMT)-associated factor linked to poor immunotherapeutic response. Tumors with high TWIST1 expression displayed reduced CD8⁺ T-cell infiltration, attenuated cytotoxic immune signatures, and unfavorable clinical outcomes. To interfere with this EMT-associated immune resistance, we developed oxidized hyaluronic acid/oxidized dextran-thioketal nanogels (OO-TK NGs) for the localized delivery of small interfering RNA targeting TWIST1 (siTWIST1), termed siTWIST1@OO-TK NGs. The nanogel was constructed from oxidized hyaluronic acid and oxidized dextran, crosslinked through a thioketal-containing bis-hydrazide linker that undergoes degradation under acidic and reactive oxygen species (ROS)-rich tumor-mimic conditions. This design enabled controlled intracellular release of siTWIST1 in tumor cells. TWIST1 silencing restored E-cadherin expression while reducing Vimentin and matrix metalloproteinase-9 (MMP9) levels, accompanied by diminished proliferation, and migration. Therapeutic efficacy was evaluated in Lewis lung carcinoma (LLC) tumor-bearing mice. Administration of siTWIST1@OO-TK NGs suppressed intratumoral TWIST1 expression, delayed tumor progression, and extended survival. The effect became more pronounced when combined with programmed cell death protein 1 (PD-1) blockade treatment, which increased CD8+ T-cell infiltration and enhanced IFN-γ-related effector activity within tumors. In a lung metastasis model, combination therapy markedly reduced metastatic burden and MMP9 expression, consistent with partial reversal of the EMT-associated markers. These findings support the potential of combining microenvironment-responsive TWIST1-targeted siRNA delivery with PD-1 blockade to concurrently modulate tumor plasticity and antitumor immunity. STATEMENT OF SIGNIFICANCE: Immune checkpoint blockade has reshaped the treatment landscape of non-small cell lung cancer (NSCLC), yet resistance remains a major clinical obstacle. Increasing evidence suggests that epithelial-mesenchymal transition (EMT) contributes to this resistance by establishing an immune-excluded tumor microenvironment that limits cytotoxic T-cell infiltration and function. In this study, through integrated analyses of immunotherapy-resistant organoid transcriptomes and clinical datasets, we identify TWIST1 as a key regulator linking EMT activation to impaired antitumor immunity and poor response to PD-1 blockade. Based on these findings, we developed a dual-responsive hydrogel nanogel system for tumor-selective delivery of siTWIST1. The nanogel undergoes degradation under acidic and reactive oxygen species-rich conditions characteristic of the tumor microenvironment, enabling controlled intracellular release of siRNA. TWIST1 silencing reversed EMT-associated phenotypes, suppressed tumor invasion and metastasis, and substantially enhanced the therapeutic efficacy of anti-PD-1 treatment in vivo through increased CD8⁺ T-cell infiltration and restoration of IFN-γ-associated immune activity.
    Keywords:  PD-1 immunotherapy; TWIST1; epithelial-mesenchymal transition; lung cancer; pH/ROS-responsive nanogels
    DOI:  https://doi.org/10.1016/j.actbio.2026.11.027
  27. Curr Med Chem. 2026 Nov 13.
       BACKGROUND: As a leading cause of cancer mortality, non-small-cell lung cancer (NSCLC) remains a major clinical challenge. Pembrolizumab plus chemotherapy is an established treatment strategy for NSCLC, but the cellular and molecular features associated with this treatment context remain to be comprehensively explored.
    METHODS: Single-cell RNA sequencing data (GSE229353) from five NSCLC patients receiving pembrolizumab plus chemotherapy and one receiving chemotherapy alone were analyzed. After quality filtering, SCTransform normalization, PCA, Harmony integration, and unsupervised clustering, Cytotoxic T cells were further subclustered. Cell-cell communication, pseudotime trajectory, sample-level pseudobulk differential expression and Hallmark GSEA, transcription factor activity, and in silico CXCL13 perturbation analyses were performed.
    RESULTS: Ten major cell types and five Cytotoxic T cell subclusters were identified, including a CXCL13+ exhausted CD8+ T cell population enriched in T cell receptor and PD-1/PD-L1 checkpoint-related pathways. CellChat revealed extensive predicted interactions with immune and stromal populations. Pseudotime analysis placed this population in intermediate-to-late regions of a continuous transcriptional trajectory. Sample-level pseudobulk analysis of the CXCL13+ exhausted CD8+ T cell subset showed exploratory enrichments of TNF/NF-κB and MYC-associated programs in the PD-1 + Chemo group and stronger interferon-response signatures in the Chemo group. The archived VIPER activity differences were summarized descriptively without significance claims. CXCL13 perturbation was associated with predicted changes in immune-related and metabolic pathways.
    DISCUSSION: The CXCL13+ exhausted CD8+ T cell population was observed in both treatment groups in NSCLC, exhibiting immune checkpoint enrichment, dynamic transcriptional states, predicted intercellular communication, and exploratory treatment-context- associated transcriptional differences. Computational perturbation analysis further suggested network-level associations involving CXCL13. These findings provide a cellular and molecular framework for further investigation, although validation in larger cohorts and experimental models remains necessary.
    CONCLUSION: These findings characterize a CXCL13+ exhausted CD8+ T cell state observed in both treatment groups and provide hypotheses for further investigation. Given the small and highly unbalanced sample size and the computational nature of the analyses, independent cohort and experimental validation are required.
    Keywords:  CD8+ T cell exhaustion; CXCL13; Chemotherapy; immune checkpoint blockade; non-small cell lung cancer; pembrolizumab; single-cell RNA sequencing; tumor immune microenvironment
    DOI:  https://doi.org/10.2174/0109298673549896260917050453
  28. Ther Adv Med Oncol. 2026 ;18 17588359261494277
      HER2-positive early breast cancer (EBC) accounts for 15-20% of breast cancer cases and is characterized by aggressive biology, though outcomes have significantly improved with HER2-directed therapies. This narrative review summarizes contemporary approaches to personalize systemic treatment of HER2-positive EBC through de-escalation and escalation strategies. In stage I disease, abrogated regimens such as paclitaxel plus trastuzumab provide excellent long-term outcomes, while ongoing studies have, and are, evaluating chemotherapy-free strategies and shorter treatment durations. In stage II-III disease, neoadjuvant therapy facilitates response-adapted management using pathologic complete response (pCR) as a functional biomarker to either de-escalate or escalate systemic therapy (including standard and emerging treatment options). Increasing evidence supports omission of anthracyclines and selective carboplatin use to minimize toxicity without compromising efficacy. Biomarkers-including intrinsic subtypes, tumor-infiltrating lymphocytes, circulating tumor DNA, and advanced imaging modalities such as FDG-PET and MRI-are increasingly included in risk stratification and treatment selection. Adaptive platform trials further support biomarker-driven initiatives to personalize care. Ongoing efforts aim to refine patient selection, optimizing outcomes while minimizing treatment-related toxicity, which is critical to driving further advancements in the field.
    Keywords:  HER2-positive; HER2DX; TILS; biomarkers; ctDNA; early breast cancer; treatment de-escalation; treatment escalation
    DOI:  https://doi.org/10.1177/17588359261494277
  29. Front Immunol. 2026 ;17 2025912
      
    Keywords:  breast cancer; immunotherapy; model systems; predictive biomarkers; spatial omics; tumor microenvironment - TME
    DOI:  https://doi.org/10.3389/fimmu.2026.2025912
  30. Front Med (Lausanne). 2026 ;13 2004545
      Chondrosarcoma is a biologically heterogeneous bone malignancy for which surgery remains the principal curative treatment, while systemic options for unresectable or metastatic disease are limited. Immune checkpoint blockade has produced occasional durable responses, particularly in dedifferentiated chondrosarcoma, but clinical activity is inconsistent and validated treatment-selection biomarkers are lacking. This Mini Review synthesizes chondrosarcoma-specific evidence on PD-L1, CD8-positive tumor-infiltrating lymphocytes, HLA class I (HLA-I)/β2-microglobulin integrity, the CD68/CD8 ratio, CSF1R-positive tumor-associated macrophages (TAMs), granulocytic myeloid-derived suppressor cells (G-MDSCs), B7-H3, and immune-phenotype classification. These markers capture complementary immune-escape processes but are largely descriptive, prognostic, or mechanistic rather than prospectively validated predictors of checkpoint-inhibitor benefit. IDH1/2 mutations and D-2-hydroxyglutarate (D-2HG) provide an additional metabolic framework, although direct evidence connecting D-2HG with immune escape in chondrosarcoma remains incomplete. The multicenter, non-randomized phase 2 FLAIL-C study reported higher 6-month progression-free survival with anti-PD-1 plus anlotinib than with anlotinib alone, particularly in dedifferentiated disease; its non-randomized design limits causal interpretation. Future subtype-stratified trials should test composite, spatially informed panels and assess mutant-IDH inhibition, myeloid modulation, and B7-H3-directed cellular therapy, the last of which remains preclinical in chondrosarcoma.
    Keywords:  IDH; PD-1; PD-L1; biomarker; chondrosarcoma; immune escape; precision immunotherapy; tumor-associated macrophage
    DOI:  https://doi.org/10.3389/fmed.2026.2004545
  31. Cancer Immunol Immunother. 2026 Aug 20. pii: 283. [Epub ahead of print]75(12):
      The complex spatial cellular interactions of immune cell populations within melanoma can provide insight into immune functions occurring within tumors. Tertiary lymphoid structures (TLSs) and B cell aggregates (BssCAs) are key features in the immunospatial tumor microenvironment (isTIME), yet are difficult to accurately detect and are poorly understood in primary melanoma. This study utilized mIHC and novel spatial analysis methods to characterize the isTIME of primary melanomas to identify associations between T cells, B cells, NK cells, Langerhans cells and patient outcome. Spatial profiling of 55 primary melanomas identified that immune neighborhood metaclusters (NMCs) enriched for either B cells, CD39+CD103+ CD8+ T cells or Langerhans cells were associated with improved rates of 5-year recurrence-free survival (RFS), while a BCA subtype harboring CD103-PD-1+ CD8+ T cells was associated with melanoma recurrence. Further analysis revealed that BCAs with higher proportions of CXCL13+ B cells were linked with reduced Breslow thickness and absence of ulceration in the primary tumor. Furthermore, the polarization of the isTIME toward B cell rather than CD38+ cell-dominant BCAs was associated with reduced ulceration and a smaller Breslow thickness. This study highlights the significance of immune neighborhoods containing CD39+CD103+ CD8+ T cells, CXCL13 expression in BCAs and their polarization as prognostic indicators in primary melanoma.
    Keywords:  Biomarkers; CD103; CD39; Primary melanoma; Prognosis; Recurrence; Spatial immunology; Spatial profiling; Tertiary lymphoid structures (TLS); Tissue-resident memory T cells (TRM); Tumor immune microenvironment; Tumor-reactive CD8 T cells
    DOI:  https://doi.org/10.1007/s00262-026-04514-9
  32. J Vis Exp. 2026 Nov 13.
      Chimeric antigen receptor (CAR) T-cell therapy has demonstrated remarkable clinical success in hematological malignancies but remains limited in solid tumors by on-target off-tumor toxicity and the inability to precisely control therapeutic activity within the tumor microenvironment. This protocol presents a workflow for localized, spatiotemporal activation of engineered CAR T cells using focused ultrasound (FUS)-induced hyperthermia. Engineered T cells containing heat shock promoter (HSP)-regulated gene circuits (EchoBack CAR T cells) remain functionally latent until activated by localized hyperthermia. The protocol describes the generation of a subcutaneous prostate cancer mouse model, local subcutaneous administration of EchoBack chimeric antigen receptor T cells proximal to the tumor, accurate alignment of the focused ultrasound transducer, and localized thermal stimulation. A central feature of the workflow is a focused ultrasound system integrated with a closed-loop proportional-integral-derivative (PID) controller that continuously adjusts acoustic power using real-time intratumoral temperature measurements obtained with a needle thermocouple. This feedback-controlled approach maintains hyperthermia at approximately 43°C for 15 min while limiting temperature fluctuations. Hardware assembly instructions, software code, and experimental procedures are provided to facilitate reproducible implementation. This protocol enables spatially controlled activation of engineered chimeric antigen receptor T cells within tumors and provides bioengineers and immunologists with a practical platform for investigating ultrasound-responsive synthetic biology and controllable cellular immunotherapies in preclinical mouse models.
    DOI:  https://doi.org/10.3791/72572
  33. Hum Gene Ther. 2026 Nov 20. 10430342261506071
      Oncolytic viruses (OVs) have emerged as versatile cancer immunotherapeutic agents that selectively kill tumor cells while simultaneously inducing antitumor immune responses. The therapeutic activity of OVs can be further enhanced by arming them with immunomodulatory transgenes. However, expression of a single transgene often fails to generate durable antitumor immunity, largely because of the complex, immunosuppressive nature of the tumor microenvironment (TME). To overcome this limitation, recent advances in OV engineering have focused on co-expression of multiple immunomodulatory payloads, including a combination of cytokines, cytokine receptors, costimulatory molecules, chemokines, immune checkpoint inhibitors (ICIs), bispecific T-cell engagers, viral antigens, and tumor antigens. Increasing evidence indicates that multi-transgene-armed OVs can more effectively promote dendritic cell maturation, enhance intratumoral infiltration and activation of CD8+ T cells and natural killer cells, elevate effector-to-regulatory T-cell ratios, remodel immunosuppressive TMEs, and synergize with other immunotherapies, including ICI and adoptive cell therapy. Despite growing interest in this field, a comprehensive review focused specifically on the immunological mechanisms, therapeutic efficacy, and translational challenges of multi-transgene-expressing OVs remains lacking. In this review, we summarize multi-transgene-armed OVs, highlighting the mechanistic rationale underlying transgene combinations, outlining their antitumor effects across preclinical settings, and discussing key design principles for next-generation OV-based immunotherapies.
    Keywords:  antitumor immunity; armed oncolytic viruses; cancer immunotherapy; cytokine co-expression; immunomodulatory transgenes; oncolytic viruses
    DOI:  https://doi.org/10.1177/10430342261506071